Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2026, 8(3); doi: 10.25236/IJFM.2026.080305.

Metabolic and Molecular Mechanisms of WGX-50 in Alzheimer’s Disease through an Integrative in Vivo and in Silico Approach

Author(s)

Muyan Liu

Corresponding Author:
Muyan Liu
Affiliation(s)

Germantown Friends School, Philadelphia, United States

Abstract

A mechanistic explanation of how WGX-50 mediates AD-plasm involves processes related to aging: metabolic disturbance, mitochondrial oxidative stress, and dysregulated proteostasis. This will determine whether WGX-50 coordinates a concerted in vivo metabolic remodeling of central carbon and redox metabolism and surface destabilization of early toxic amyloid-beta (Aβ1–42) in silico. Targeted LC–MS/MS metabolomics on the WT in the WGX-50 treated worms or vehicle will be performed, with n ≥5 biological replicates per group, for the quantification of glycolytic, tricarboxylic acid (TCA) cycle, pentose phosphate pathways, and redox/energy cofactor pool metabolites, normalized to total protein and assessed by quality control, univariate statistics, false discovery rate, principal component analysis, clustering, and pathway analyses. All-atom MD simulations of oligomers, whether unbound or bound by WGX-50, were set up for a total of at least three to four independent trajectories. The loss of oligomerization was estimated by the progressive decrease in inter-chain van der Waals contacts, beta-sheet content, structural parameters (RMSD, RMSF, SASA, and radius of gyration), and a detailed MM/GBSA energetic quantification. We anticipate that WGX-50 will induce a concerted metabolic shift in energy sensing and redox balance while disrupting inter-peptide interactions and increasing the oligomer conformational entropy. In such integrative experiments, metabolic profiling, organismal assays, and atomistic simulations are combined so that a mechanistic hypothesis can be built on putative anti-oxidative and anti-aggregative effects of WGX-50 relevant to AD proteotoxicity.

Keywords

WGX-50, Alzheimer’s Disease, Targeted Metabolomics, Molecular Dynamics Simulation

Cite This Paper

Muyan Liu. Metabolic and Molecular Mechanisms of WGX-50 in Alzheimer’s Disease through an Integrative in Vivo and in Silico Approach. International Journal of Frontiers in Medicine (2026), Vol. 8, Issue 3: 39-44. https://doi.org/10.25236/IJFM.2026.080305.

References

[1] Knopman D S, Amieva H, Petersen R C, et al. Alzheimer disease[J]. Nature Reviews Disease Primers, 2021, 7(1):33.

[2] Van Dyck C H, Swanson C J, Aisen P, et al. Lecanemab in early Alzheimer’s disease[J]. The New England Journal of Medicine, 2022, 388: 9-21.

[3] Karran E, de Strooper B. The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics[J]. Nature Reviews Drug Discovery, 2022, 21(4): 306-318.

[4] Tai P, Chen X, Jia G, et al. WGX50 Mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis[J]. Journal of Translational Medicine, 2023, 21(1): 823.

[5] Case D A, Aktulga H M, Belfon K, et al. AmberTools[J]. Journal of Chemical Information and Modeling, 2023, 63(20): 6183-6191.

[6] Roe D R, Cheatham T E. Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data[J]. Journal of Computational Chemistry, 2018, 39(25): 2110-2117.

[7] Olsson M H M, Søndergaard C R, Rostkowski M, et al. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions[J]. Journal of Chemical Theory and Computation, 2011, 7(2): 525-537.

[8] Miller B R, McGee T D, Swails J M, et al. MMPBSA.py: An efficient program for end-state free energy calculations[J]. Journal of Chemical Theory and Computation, 2012, 8(9): 3314-3321.

[9] Lu T, Chen Q X. Independent gradient model based on Hirshfeld partition: A new method for visual study of interactions in chemical systems[J]. Journal of Computational Chemistry, 2022, 43(8): 539-555.

[10] Han Y L, Yin H H, Xiao C, et al. Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation[J]. ACS Chemical Neuroscience, 2023, 14(22): 4051-4061.